When HIVE first revealed itself everyone was on pins and needles because of the lack of information. HIVE has developed many stereotypes. Many of the social stereotypes attached to people living with HIVE/AIDS are incorrect. Since the late sass the improve antiviral drug therapy has led to a better or “normal” life for infected individuals. Antiviral therapies are not the easiest to come by and insurance companies are complicated when it comes to infected patients with HIVE/AIDS.
Along with the cost there are different types of drug therapies and some are more effective than others. According to Michael Lodestone’s Viruses, Plagues and History today there are huge advancements in drug therapy has reduced the WIDTHS death rates by two-thirds. In the early sass in United States the death rate was less great (251). But the early twenty-first century antiviral drug therapies have since improved. The earlier the treatment begins the better the prognoses, some infected patients delay treatment until they see symptoms.
In doing so leads to a poorer outcome (Lodestone 252). A longer life expectancy correlates tit the shortest time interval between HIVE infection, diagnosis, and start of antiviral medical therapy (Lodestone 252). There are improvements in testing for HIVE infected persons. There are two tests, CDC count and HIVE viral load. Both help healthcare provides know the strength of your immune system. CDC cells help your immune system function but the HIVE virus comes in and kills those CDC cells. However the CDC count test tells how many CDC cells you have and the higher the count the better.
The second test health care providers administer is the HIVE viral load test. This test determines how much f the HIVE virus is present in your blood and how fast is it growing. The higher the viral load is equivalent to how fast the virus is infecting and how fast the virus is killing your CDC cells. Once your healthcare provider receives these result they can tell how urgent to start intergenerational drug therapy. With these advancement in testing HIVE can be diagnosed much faster (HIVE Persistence and the Prospect of Long-Term Drug-Free Remissions for HIVE-linefeed Individuals).
There has since been many different intergenerational drugs and they work by attacking the HIVE virus directly and the drugs cripple the ability Of the virus to make copies Of it. For most antiviral drugs the plan of attack would be to clear the HIVE from the body and block all viral replication. Most of the therapeutic methods involve combination therapy with 3 or more antiviral drugs. This method decreases the viral burden. The main 2 drugs for intergenerational (ARP) therapy are the Nucleotide Reverse Transcripts Inhibitors (Unrest) and Chamomile Corrector Antagonists (CRY).
The Unrest drugs blocks the enzyme reverse transcripts from converting the HIVE virus genetic material from RNA to DNA which helps the virus mature (Can HIVE be Cured? ) Two examples of drug ambitions are indicator, guideline, and landmine or inoperative, guideline, and adenosine (Public Health Implications of Intergenerational Therapy and HIVE Drug Resistance). These Martin can be combined into one TABLEt. The other drug therapies for ARP are CRY, which blocks the infection by interfering with the ability of the virus to bind to a molecular receptor known as Chamomile Corrector. CRY is just one TABLEt.
Thus, the combination antiviral regimens used must have blocked viral replication to the extent that the mutations that encode drug resistance could not occur. Medications for HIVE are taken daily come with a hefty price tag. According to Michael Lodestone’s Viruses, Plague and History the enhanced life expectancy of those infected and on medication leads to a high medical cost per individual. The cost of medical cost of his/her predicted lifespan approximately twenty-five years after their HIVE diagnoses are about $600,000 to $650,000. This amount covers drugs and medical visits (255).
The cost of HIVE/AIDS patients increases substantially as HIVE diseases progress. HIVE care and treatment involves a commitment to ongoing visits with your health care provider, tests to monitor your health status, and medications. These things re important because with the proper care and treatment, you can reduce your viral load, protect your health, enjoy a long and healthy life, and reduce the potential of transmitting the virus to others (The Cost Effectiveness of Combination Intergenerational Therapy for HIVE Disease). But you might have concerns about how to pay for this.
There are resources that can help you pay for the care you need. The cost of treatment started at this late stage averages $4,700 per month. That’s because hospital costs rise to almost half the lifetime expenses. In the last 10 years, the U. S. Has tripled its spending on HIVE-related medical care. With three-drug therapy, as compared with no therapy, the life expectancy was 3. 51 years (2. 91 quality-adjusted years), the lifetime cost was $77,300, and the incremental cost per quality-adjusted year of life was $23,000 (The Cost Effectiveness of Combination Intergenerational Therapy for HIVE Disease).
The higher CDC Cell Counts started the three-drug therapy when the patient presented with a CDC cell count that was 500 per cubic millimeter (and an HIVE RNA level that exceeded 30,000 copies per millimeter) increased total lifetime costs from $64,210 to $90,980 and increased quality-adjusted life expectancy from 5. 10 to 6. 4 years, with an incremental cost Of $15,000 per quality-adjusted year Of life gained, as compared with no therapy. This approach was more effective and a more efficient use of resources than starting therapy when the CDC cell count was 350 per cubic millimeter. ,5 Waiting until the CDC cell count was 200 per cubic millimeter resulted in higher total costs and a lower quality-adjusted life expectancy.
With the improved efficacy reported in more recent trials, 18 the cost- effectiveness ratio for therapy initiated when the CDC cell count was 500 per cubic millimeter was decreased to $11 ,OOH per quality-adjusted year of life mined (The Cost Effectiveness of Combination Intergenerational Therapy for HIVE Disease). Michael Lodestone says the current patients with HIVE are living longer with fewer disease symptoms.
The reason behind that was the development of anti-HIVE medications now formulated to only one pill a day is needed (Lodestone 253). People with HIVE may enjoy life spans close to normal if they maintain low viral loads and CDC counts above 350. Furthermore, those who survive past 60 may have life expectancies that surpass normal; thanks to the better overall health care monitoring they experience compared with the general population. The Arabs contribute to maintaining a higher CDC count which leads to a promise significance of extra years of life.
For example five years into ARP treatment, 35-year-old male patients with counts between 350 and 500 could expect to live to 77 and to 81 if their CDC counts Were higher than 500. On the flip side, those who fail to develop a suppressed viral load would lose 1 1 years of life expectancy. And people whose CDC counts remain below 200 after five years on Arabs could expect to live only to 55 on average. HIVE/AIDS will always be a world epidemic. Although we are making new advances in battling this virus. The best way to stay safe is to stay informed.
